Arcturus Therapeutics (NASDAQ:ARCT) Share Price Passes Below Two Hundred Day Moving Average - What's Next?

Key Points

• Arcturus shares slipped below their 200-day moving average, trading as low as $8.20 and last at $8.22 versus the 200-day MA of $9.51, signaling technical weakness.
• Analysts remain mixed but broadly positive with an average rating of "Moderate Buy" and an average price target of $29.50, despite several recent downward revisions from firms like Citigroup and Piper Sandler.
• The company reported weak fundamentals—missing EPS and revenue estimates (Q: $(1.03) EPS; revenue $7.2M vs. $14.32M est.), negative margins and a small market cap (~$234M)—even as institutional ownership is very high (~94.5%).

Arcturus Therapeutics Holdings Inc. (NASDAQ:ARCT - Get Free Report) crossed below its 200-day moving average during trading on Thursday . The stock has a 200-day moving average of $9.51 and traded as low as $8.20. Arcturus Therapeutics shares last traded at $8.22, with a volume of 332,772 shares changing hands.

Analysts Set New Price Targets

ARCT has been the subject of several research reports. Roth Mkm initiated coverage on Arcturus Therapeutics in a research note on Thursday, January 22nd. They set a "buy" rating and a $20.00 price objective for the company. Citigroup reduced their price objective on Arcturus Therapeutics from $66.00 to $21.00 and set a "buy" rating for the company in a research note on Thursday, March 5th. Piper Sandler reduced their price objective on Arcturus Therapeutics from $72.00 to $25.00 and set an "overweight" rating for the company in a research note on Wednesday, March 4th. B. Riley Financial initiated coverage on Arcturus Therapeutics in a research note on Wednesday, March 18th. They set a "buy" rating and a $22.00 price objective for the company. Finally, Weiss Ratings reissued a "sell (d-)" rating on shares of Arcturus Therapeutics in a research note on Wednesday, January 21st. One investment analyst has rated the stock with a Strong Buy rating, eight have given a Buy rating, three have issued a Hold rating and one has issued a Sell rating to the company's stock. Based on data from MarketBeat, Arcturus Therapeutics has an average rating of "Moderate Buy" and an average price target of $29.50.

Arcturus Therapeutics Stock Performance

The firm has a market capitalization of $233.64 million, a P/E ratio of -3.45 and a beta of 2.44. The firm has a 50 day moving average price of $7.46 and a two-hundred day moving average price of $9.51.

Arcturus Therapeutics (NASDAQ:ARCT - Get Free Report) last issued its earnings results on Tuesday, March 3rd. The biotechnology company reported ($1.03) EPS for the quarter, missing the consensus estimate of ($0.92) by ($0.11). The business had revenue of $7.20 million during the quarter, compared to analyst estimates of $14.32 million. Arcturus Therapeutics had a negative return on equity of 29.13% and a negative net margin of 80.19%. Equities research analysts forecast that Arcturus Therapeutics Holdings Inc. will post -2.22 earnings per share for the current fiscal year.

Institutional Trading of Arcturus Therapeutics

Several hedge funds and other institutional investors have recently modified their holdings of ARCT. ARK Investment Management LLC boosted its position in shares of Arcturus Therapeutics by 39.4% in the fourth quarter. ARK Investment Management LLC now owns 2,611,099 shares of the biotechnology company's stock worth $16,006,000 after buying an additional 738,378 shares during the period. Arrowstreet Capital Limited Partnership boosted its position in shares of Arcturus Therapeutics by 1,371.4% in the third quarter. Arrowstreet Capital Limited Partnership now owns 552,179 shares of the biotechnology company's stock worth $10,177,000 after buying an additional 514,652 shares during the period. Millennium Management LLC acquired a new stake in shares of Arcturus Therapeutics in the first quarter worth $4,892,000. Bank of America Corp DE boosted its position in shares of Arcturus Therapeutics by 112.0% in the third quarter. Bank of America Corp DE now owns 620,055 shares of the biotechnology company's stock worth $11,428,000 after buying an additional 327,626 shares during the period. Finally, Goldman Sachs Group Inc. boosted its position in shares of Arcturus Therapeutics by 170.3% in the fourth quarter. Goldman Sachs Group Inc. now owns 391,227 shares of the biotechnology company's stock worth $2,398,000 after buying an additional 246,499 shares during the period. Institutional investors and hedge funds own 94.54% of the company's stock.

Arcturus Therapeutics Company Profile

Arcturus Therapeutics Holdings Inc is a clinical-stage biotechnology company dedicated to developing messenger RNA (mRNA) medicines that address a range of diseases. The company leverages its proprietary STARR® mRNA platform to enable precise control over mRNA expression, supported by its lipid nanoparticle delivery technology, LUNAR®. Arcturus's approach is designed to address both therapeutic and prophylactic applications, with an emphasis on vaccines and treatments for rare genetic and infectious diseases.

The company's pipeline includes ARCT-810, an mRNA therapeutic candidate for phenylketonuria (PKU), and ARCT-021 (also known as LUNAR-COV19), a COVID-19 vaccine candidate developed in collaboration with Duke-NUS Medical School in Singapore.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.